Sparteine oxidation polymorphism in Denmark
- PMID: 4090995
- DOI: 10.1111/j.1600-0773.1985.tb00058.x
Sparteine oxidation polymorphism in Denmark
Abstract
Sparteine oxidation was polymorphic among 301 healthy Danish volunteers. Hence 22 subjects or 7.3% were phenotyped as poor metabolizers (PM) whereas 279 subjects were classified as extensive metabolizers (EM). The metabolic ratio (MR) between sparteine and 2- and 5-dehydrosparteine (% of dose) in 12 hrs urine ranged from 0.11-12.6 in EM and from 30-394 in PM. Urinary excretion of 2- and 5-dehydrosparteine also discriminated between PM and EM. Age, sex, and smoking habits did not influence the MR. This study confirms that sparteine is a useful probe drug in pharmacogenetic investigations.
Similar articles
-
Sparteine oxidation polymorphism in Greenlanders living in Denmark.Br J Clin Pharmacol. 1986 Oct;22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x. Br J Clin Pharmacol. 1986. PMID: 3768256 Free PMC article.
-
Sparteine oxidation polymorphism: a family study.Br J Clin Pharmacol. 1986 Jun;21(6):661-7. doi: 10.1111/j.1365-2125.1986.tb05231.x. Br J Clin Pharmacol. 1986. PMID: 3741716 Free PMC article.
-
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.Br J Clin Pharmacol. 1989 May;27(5):620-5. doi: 10.1111/j.1365-2125.1989.tb03426.x. Br J Clin Pharmacol. 1989. PMID: 2757884 Free PMC article.
-
Polymorphic oxidation of debrisoquine and sparteine.Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
-
[The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].Ugeskr Laeger. 1991 Feb 4;153(6):417-22. Ugeskr Laeger. 1991. PMID: 2000644 Review. Danish.
Cited by
-
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.Br J Clin Pharmacol. 1990 Nov;30(5):683-91. doi: 10.1111/j.1365-2125.1990.tb03836.x. Br J Clin Pharmacol. 1990. PMID: 2271367 Free PMC article. Clinical Trial.
-
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.Br J Clin Pharmacol. 1993 Aug;36(2):105-8. doi: 10.1111/j.1365-2125.1993.tb04204.x. Br J Clin Pharmacol. 1993. PMID: 8398577 Free PMC article.
-
Genetically determined sparteine oxidation polymorphism in a Polish population.Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917. Eur J Clin Pharmacol. 1994. PMID: 7957549 Clinical Trial.
-
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.Eur J Clin Pharmacol. 1990;39(6):533-7. doi: 10.1007/BF00316090. Eur J Clin Pharmacol. 1990. PMID: 2151318
-
S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.Br J Clin Pharmacol. 1994 Nov;38(5):463-5. doi: 10.1111/j.1365-2125.1994.tb04383.x. Br J Clin Pharmacol. 1994. PMID: 7893589 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources